Healix

Recurrent Clostridioides Difficile Infection (CDI) Worsens Anxiety-Related Patient-Reported Quality of Life

Kevin W. Garey – University of Houston College of Pharmacy, Houston, TX
Claudia P. Schroeder – Healix Infusion Therapy, Sugar Land, TX
Thomas C. Hardin – Healix Infusion Therapy, Sugar Land, TX
Richard L. Hengel – Atlanta ID Group, Atlanta, GA
Timothy E. Ritter – Texas Digestive Disease Consultants, Southlake, TX
Ramesh V. Nathan – Mazur, Statner, Dutta, Nathan PC, Thousand Oaks, CA
Ryan. J. Dillon – Merck & Co., Inc., Kenilworth, NJ
Lucinda J. Van Anglen – Healix Infusion Therapy, Sugar Land, TX

View Poster

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.

FacebookTwitterLinkedInarrow1arcsearchiconowdtnotfound